Sun, May 19, 2013, 3:22 AM EDT - U.S. Markets closed
GSK needs to find a replacement for Avandia. Biodel meets their criteria on several levels. http://www.reuters.com/article/idUSTRE66P13K20100726Biodel is substantially undervalued relative to both its short term and long term potential.
"SNY" has spent $17 billion for 25 small bio-tech companies in the last two years. Biodel fits the profile of the acquired companies perfectly. Average price tag:$685,000,000
BIOD will NEVER be sold for under $1B.
SNY has spent $17 billion on 25 acquisitions in the last two years. Don't dismiss them as a potential suitor.
$15.00 by the end of the year sounds reasonable.
"GSK or SNY"!!!It's all good!!!
The longs can use all the cheap shares that the shorts want to give them here.
Add a few shares before the run higher begins in earnest. Market is just starting to be made aware of the upside with Biodel.